Compare XLO & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XLO | RAND |
|---|---|---|
| Founded | 2016 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 41.2M |
| IPO Year | 2021 | N/A |
| Metric | XLO | RAND |
|---|---|---|
| Price | $0.65 | $16.90 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 528.0K | 4.7K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 7.27% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,804,000.00 | $7,327,287.00 |
| Revenue This Year | $589.60 | N/A |
| Revenue Next Year | $38.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 588.40 | N/A |
| 52 Week Low | $0.62 | $13.25 |
| 52 Week High | $1.70 | $31.89 |
| Indicator | XLO | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 80.23 |
| Support Level | $0.68 | $15.65 |
| Resistance Level | $0.73 | $15.49 |
| Average True Range (ATR) | 0.04 | 0.56 |
| MACD | -0.01 | 0.29 |
| Stochastic Oscillator | 10.24 | 94.22 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.